KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

Opinion
Video

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Recent Videos
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Related Content
3 Things You Should Know About the Multimodal Treatment of SCLC

3 Things You Should Know About the Multimodal Treatment of SCLC

Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
May 19th 2025
Article

Here are 3 things you should know about the multimodal treatment of patients with SCLC.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.

Low-Dose CT Screening for Lung Cancer Shows Large-Scale Efficacy

Russ Conroy
April 29th 2025
Article

Study data show a small number of individuals with a lung cancer diagnosis within 12 months of a negative baseline screening result.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.

Lung Cancer Screening Adherence Decreases Across Subsequent Testing

Russ Conroy
April 24th 2025
Article

Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

Russ Conroy
April 23rd 2025
Article

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.